Laddar...
CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy
Castration-resistant prostate cancer (CRPC) is an androgen receptor (AR)-dependent disease expected to cause the death of more than 27,000 Americans in 2015. There are only a few available treatments for CRPC, making the discovery of new drugs an urgent need. We report that CUDC-101 (an inhibitor od...
Sparad:
| I publikationen: | Horm Cancer |
|---|---|
| Huvudupphovsmän: | , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Springer US
2016
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4896833/ https://ncbi.nlm.nih.gov/pubmed/26957440 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12672-016-0257-2 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|